Syra Health (SYRA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for 2025 to elect five directors, ratify the auditor, and vote on two amendments to the certificate of incorporation.
Voting available by internet, mail, or in person; record date set for 2025.
Proxy materials accessible online, with householding practices in place for cost efficiency.
Voting matters and shareholder proposals
Four proposals: election of five directors, ratification of M&K CPAS, PLLC as auditor, deletion of automatic conversion of Class B stock upon death, and amendment to allow Class B transfers to family/heirs without conversion.
Board recommends voting FOR all proposals.
Shareholders may submit proposals for the 2026 meeting by deadlines in the bylaws and SEC rules.
Board of directors and corporate governance
Board consists of five nominees, with three independent directors as per Nasdaq and SEC rules.
Committees: Audit, Compensation, and Nominating & Governance, all with independent members.
Code of Business Conduct and Ethics in place; insider trading and anti-hedging policies enforced.
No Chairman; board meets regularly, with independent sessions.
Board diversity and qualifications considered, but no formal diversity policy.
Latest events from Syra Health
- Returned to profitability with 23% revenue growth, record margins, and strong contract performance.SYRA
Q2 2026 - Director elections, auditor ratification, and equity plan share increase up for vote.SYRA
Proxy filing - Shareholders will vote on board elections, auditor ratification, and expanding the equity plan.SYRA
Proxy filing - First profitable quarter with 22% revenue growth and improved margins, driven by high-margin solutions.SYRA
Q1 2026 - Population Health revenue up 157% and net loss down 76%, targeting profitability by 2026.SYRA
Q4 2025 - Healthcare firm files $75M shelf registration amid growth plans and financial uncertainty.SYRA
Registration Filing - Healthcare firm targets $75M shelf offering amid growth plans and financial risks.SYRA
Registration Filing - Q3 2024 revenue up 42%, margins improved, but losses and delisting risk persist.SYRA
Q3 2024 - 2024 revenue up 45% to $8M, Q4 net loss nearly halved, strong Population Health growth.SYRA
Q4 2024